News Focus
News Focus
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

Re: DewDiligence post# 8574

Thursday, 02/09/2012 10:53:46 AM

Thursday, February 09, 2012 10:53:46 AM

Post# of 20689
The new guidance for operating cash burn excluding collaborative revenue from NVS (effectively reimbursement for MNTA’s R&D) and excluding MNTA’s small Lovenox royalty payable to MIT is $22-28M per quarter.

The above guidance includes an unspecified amount for MNTA’s portion of ongoing legal fees for the Lovenox patent case. (NVS pays 100% of the ongoing legal fees in the Copaxone patent case.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”